Further studies on the natriuretic activity of p-hydroxytriamterene.
p-Hydroxytriamterene, the phase I metabolite of triamterene, increased sodium excretion without affecting urinary volume or potassium when administered orally to rats on sodium deficient diets at doses of 15 and 30 mg/kg. The urine of these animals also contained p-hydroxytriamterene sulfuric acid ester, the phase II metabolite of triamterene but did not contain p-hydroxytriamterene. This evidence indicates that p-hydroxytriamterene is orally active as a potassium-sparing natriuretic in rats.
D000818:Animals; D008297:Male; D009318:Natriuresis / Q000187:drug effects*; D011188:Potassium / Q000652:urine; D051381:Rats; D014223:Triamterene / Q000031:analogs & derivatives* / Q000494:pharmacology
C029656:4-hydroxytriamterene; D011188:Potassium; D014223:Triamterene